TOPIC 3 - P2 Flashcards
(Direct Antiglobulin Test)
detects in vivo sensitization of RBCs with _____ or __________
IgG or complement components
(Direct Antiglobulin Test)
conditions that can result in in vivo coating of RBCs with antibody or complement are:
- Hemolytic disease of the newborn (HDN)
- Hemolytic transfusion reaction (HTR)
- Autoimmune and drug-induced hemolytic anemia (AIHA)
not a required test in routine pretransfusion protocols
(Direct Antiglobulin Test)
(Direct Antiglobulin Test)
Positive results are monitored by a _______ using monospecific anti-IgG and anti-C3d to determine the specific type of protein sensitizing the cell.
DAT panel ;
(Direct Antiglobulin Test)
In an effort to save valuable tech time, some institutions run ______ and ______ reagents at one time as well as a _______
The ________ serves to detect _______ of cells or reactions occurring without the addition of AHG reagents.
polyspecific and monospecific ; saline control
- saline control ; spontaneous agglutination
(Direct Antiglobulin Test)
In the investigation of ______, protein sensitizing the newborn RBCs is presumed to be _______.
HDN ; maternal IgG
(Direct Antiglobulin Test)
other techniques can be used to remove antibody from the patient’s RBCs these includes _________, __________, and _________
chloroquine diphosphate, EDTA-glycine, and murine monoclonal antibodies
(Evaluation of a Positive DAT)
AABB Technical Manual states that “__________”
a positive DAT alone is not diagnostic
(Evaluation of a Positive DAT)
Interpreting the significance of a positive DAT requires knowledge of the _________, _________, ________, and _________
patient’s diagnosis, pregnancy, drug therapy, and recent transfusion history
(DAT)
CLINICAL APPLICATION:
HDN
HTR
AIHA
IN VIVO SENSITIZATION:
Maternal antibody coating fetal RBCs
Recipient antibody coating donor RBCs
Autoantibody coating individual’s RBCs
DAT PANEL: PATTERNS OF REACTIVITY IN AUTOIMMUNE HEMOLYTIC ANEMIA
Type of AIHA: WAIHA
Anti-IgG: +
Anti-C3d: +
DAT PANEL: PATTERNS OF REACTIVITY IN AUTOIMMUNE HEMOLYTIC ANEMIA
Type of AIHA: WAIHA
Anti-IgG: +
Anti-C3d: -
DAT PANEL: PATTERNS OF REACTIVITY IN AUTOIMMUNE HEMOLYTIC ANEMIA
Type of AIHA: CAS; PCH, WAIHA
Anti-IgG: -
Anti-C3d: +
DAT PANEL: PATTERNS OF REACTIVITY IN AUTOIMMUNE HEMOLYTIC ANEMIA
Type of AIHA: MIXED-TYPE AIHA (cold and warm)
Anti-IgG: +
Anti-C3d: +
IN VIVO PHENOMENA ASSOCIATED WITH A POSITIVE DAT (TRANSFUSION)
CONDITION 1. ???
CAUSE 1: Alloantibodies in the recipient of a recent transfusion that react with antigen on donor RBC
Recipient alloantibody and donor antigen
IN VIVO PHENOMENA ASSOCIATED WITH A POSITIVE DAT (TRANSFUSION)
CONDITION 2. ???
CAUSE 2: Antibodies present in donor plasma that react with antigen on a transfusion recipient’s RBCs
Donor antibody and recipient antigen
IN VIVO PHENOMENA ASSOCIATED WITH A POSITIVE DAT (DRUG INDUCED)
CONDITION 1: ???
CAUSE 1: drug binds covalently to membrane proteins and stimulates hapten-dependent Ab
Type 1 (hapten-dependent Ab)
IN VIVO PHENOMENA ASSOCIATED WITH A POSITIVE DAT (DRUG INDUCED)
CONDITION 2: ?????
CAUSE 2: Drug induces autoantibody specific for RBC membrane proteins through unknown mechanism; Ab reacts with normal RBCs in the absence of drug.
Type 2/II (autoantibody)
IN VIVO PHENOMENA ASSOCIATED WITH A POSITIVE DAT (DRUG INDUCED)
CONDITION 3: ?????
CAUSE 3: Drug induces Ab that binds to RBC only when drug is present in soluble form, unknown mech; Ab reacts with normal RBCs when soluble drugs is present.
Type 3/III (drug-dependent Ab)
IN VIVO PHENOMENA ASSOCIATED WITH A POSITIVE DAT (AUTOIMMUNE HEMOLYTIC ANEMIA)
CONDITION 1: ????
CAUSE 1: autoantibody reacts with patient’s RBCs in vivo
WAIHA (IgG or/and C3)
IN VIVO PHENOMENA ASSOCIATED WITH A POSITIVE DAT (AUTOIMMUNE HEMOLYTIC ANEMIA)
CONDITION 2: ???
CAUSE 2: Cold-reactive IgM autoagglutinin binds to RBCs in peripheral circulation (32 deg celsius). IgM binds complement as RBCs return to warmer parts of circulation; IgM dissociates, leaving RBCs coated only with complement.
CAS (C3)
IN VIVO PHENOMENA ASSOCIATED WITH A POSITIVE DAT (AUTOIMMUNE HEMOLYTIC ANEMIA)
CONDITION 3: ????
CAUSE 3: The IgG autoantibody reacts with RBCs in colder parts of the body, causes complement to be bound irreversibly to RBCs, and then elutes at warmer temperature.
PCH (IgC)
IN VIVO PHENOMENA ASSOCIATED WITH A POSITIVE DAT (HDN)
CONDITION 1: ????
CAUSE 1: Maternal IgG alloantibody, specific for fetal antigen, coats fetal RBCs. DAT is reactive with anti-IgG
MATERNAL ALLOANTIBODY CROSSES PLACENTA (IgG)
IN VIVO PHENOMENA ASSOCIATED WITH A POSITIVE DAT (MISCELLANEOUS)
CONDITION 1: ?????
CAUSE 1: Heterophile antibodies that are present in ALG or ATG coat recipient’s RBCs. High levels of protein causing red cells to spontaneously agglutinate.
ABSORBED PROTEINS; ADMINISTRATION OF EQUINE PREPARATIONS OF ANTILYMPHOCYTE GLOBULIN AND ANTITHYMOCYTE GLOBULIN
IN VIVO PHENOMENA ASSOCIATED WITH A POSITIVE DAT (MISCELLANEOUS)
CONDITION 2: ????
CAUSE 2: Non-antibody-mediated binding of immunoglobulin to RBCs in patients with hypergammaglobulinemia
ADMINISTRATION OF HIGH-DOSE IV GAMMA GLOBULIN AND HYPERGAMMAGLOBULINEMIA
performed to determine in vitro sensitization of RBCs
Indirect Antiglobulin Test
Indirect Antiglobulin Test is used in the following situations:
- Detection of incomplete (nonagglutinating) antibodies to potential donor RBCs (compatibility testing) or to screening cells (antibody screen) in serum
- Determination of RBC phenotype using known antisera (e.g., Kell typing, weak D testing)
- Titration of incomplete antibodies
(Indirect Antiglobulin Test)
APPLICATION: Antibody detection
TEST:
IN VITRO SENSITIZATION: Recipient antubody reacting with donor cells
Compatibility Testing
(Indirect Antiglobulin Test)
APPLICATION: —-
TEST:
IN VITRO SENSITIZATION: Antibody reacting with screening cells
Antibody screening (TEST)
(Indirect Antiglobulin Test)
APPLICATION: Antibody identification
TEST:
IN VITRO SENSITIZATION: Antibody reacting with panel cells
Antibody panel